McKenna's Pharmacology for Nursing, 2e

280

P A R T 3  Drugs acting on the immune system

TABLE 18.1

DRUGS IN FOCUS Vaccines (continued)

Drug name

Dosage/route

Usual indications

Toxoids diphtheria and tetanus toxoid (ADT Booster) diphtheria and tetanus toxoid and pertussis vaccine (Adacel, Boostrix) diphtheria and tetanus toxoid and pertussis vaccine (Tripacel) diphtheria and tetanus toxoid, pertussis and poliomyelitis vaccine (Adacel Polio, Boostrix- IPV, Quadracel) diphtheria and tetanus toxoid, pertussis and poliomyelitis vaccine (Infanrix IPV ) diphtheria and tetanus toxoid, and hepatitis B, pertussis and poliomyelitis vaccine (Infanrix Penta) diphtheria and tetanus toxoid, and hepatitis B, pertussis, poliomyelitis and Haemophilus influenzae vaccine (Infanrix Hexa) Viral vaccines H1N1 pandemic influenza vaccine (Panvax)

0.5 mL IMI

Reimmunisation in adults and children >5 years Immunisation in adults and children >10 years Primary immunisation children 6 weeks or older Booster immunisation in adults or children >4 years

0.5 mL deep IMI

0.5 mL IMI at 2, 4, 6, 18 months and booster 4–6 years

0.5 mL deep IMI

0.5 mL by deep IMI

Primary immunisation in children 6 weeks or older

0.5 mL IM at 2, 4, 6 months

Primary immunisation in children 6 weeks or older

0.5 mL IM at 2, 4, 6 months

Primary immunisation in children 6 weeks or older

Adult or paediatric >36 months: 0.5 mL IMI or deep SC Paediatric 6–35 months: 0.25 mL IMI or deep SC Adults and paediatric >10 years: single dose Paediatric 6 months–10 years: 2 doses at least 4 weeks apart Adult: 1 mL IM with a booster dose in 6–12 months Paediatric: 0.5 mL IM with a repeat dose in 6–12 months 1 mL IM followed by booster doses at 1 and 6 months

Active immunisation against H1N1 influenza

hepatitis A vaccine, inactivated (Avaxim, Havrix,VAQTA)

Immunisation of adults and children against hepatitis A infection

hepatitis A vaccine, inactivated, with hepatitis B recombinant vaccine (Twinrix) hepatitis B vaccine (Energix-B, H-B-Vax II)

Immunisation against hepatitis A and hepatitis B infections in people ≥18 years of age Immunisation against hepatitis B infections in susceptible people and in infants born to mothers with hepatitis B Active immunisation against human papillomavirus responsible for causing genital warts and many cervical cancers Prophylaxis in adults and children at high risk for complications of influenza infections Immunisation of persons >1 year of age who reside in or will travel to endemic areas

0.5–1 mL IM, followed by 0.5–1 mL IM at 1 and 6 months

human papillomavirus, recombinant, quadrivalent (Cervarix, Gardasil)

Females 9–26 years: 0.5 mL IM, then 0.5 mL IM 2 months later, followed by 0.5 mL IM 6 months after the first dose Adult: 0.5 mL IM or deep SC Paediatric: 0.25–0.5 mL IM or deep SC, repeated in 4 weeks 1 mL SC on days 0, 7 and 30 1–3 years: 0.5 mL SC on days 0, 7 and 30

influenza virus vaccine (Fluarix, Fluvax)

Japanese encephalitis vaccine (Je-Vax)